MYC (V-myc avian myelocytomatosis viral oncogene homolog)

This is the first report of C8-HSL as a promoter of lung cancer cell proliferation, migration, and invasion. Taken together, C8-HSL is a potential risk factor for lung cancer, and strategies targeting C8-HSL-producing bacteria and monitoring C8-HSL concentrations may be beneficial for the prevention and control of lung cancer.

However, the expression levels of Oct3/4 and Nanog were significantly lower in both iTS-P OSKM2 and YAP9 cells than in the ES cells. These results conclude that no substantial difference is present in the characteristics between iTS-P cells induced by OSKM or YAP, and that their higher differentiation efficiency than the ES cells indicates promising potential for clinical applications.

PLCXD3 functions as a tumor suppressor in gastric cancer by inhibiting cell migration, invasion, and stemness through modulation of the Wnt/β-catenin pathway. Its downregulation may serve as a novel early diagnostic biomarker and a promising therapeutic target in gastric cancer management.

Our findings support HHL-5 cells as a robust non-cancerous in vitro model for investigating liver diseases, viral infection, and early events in hepatocarcinogenesis.

This review systematically summarizes the core mechanisms by which EBV contributes to lymphoma pathogenesis and evaluates the breakthroughs and challenges of current therapeutic strategies. It also outlines the future directions of precision medicine, based on multi-disciplinary integration, to enhance the understanding of the molecular pathology of EBV-associated lymphomas and optimize personalized treatment.

Crucially, clinical analysis reveals that high levels of OGT, POM121, and c-MYC positively correlate with adverse clinical outcomes. These findings establish the OGT-POM121-c-MYC-ECM axis as a potential diagnostic biomarker and a promising therapeutic target for NSCLC bone metastasis.

Furthermore, conditioned media from the treated BC cells induced the proliferation of PMA treated monocyte like THP-1 cells and provoked the secretion of IL-6, while reducing IL-10. These findings suggest that the CD151-LEL-based peptides and their engineered multiepitope construct represent a prospective vaccine candidate for in vivo experimental validation, which can be used as a therapeutic vaccine for breast cancer.

An increase in HIF-1α expression correlated with aggressive behaviour of cancer and a higher likelihood of metastatic tumours. HIF-1α inhibitors can be considered as a newer therapeutic target.

Together, these findings establish ACTL8 as a key oncogenic driver of BC progression. Targeting ACTL8 offers a novel strategy to disrupt glutamine-dependent metabolic reprogramming, and Momordin Ic represents a promising lead agent to combat ACTL8-driven BC.

Our study uncovers a "C1orf35-driven" energy metabolism model in MM cells, providing new insights into the pathogenesis of MM and a potential novel target for the treatment of cancer cells with a high"C1orf35-driven" anabolic metabolism. Schematic diagram of C1orf35 simultaneously promotes glycolysis and OXPHOS.